EGFR

シグナル伝達経路

EGFRシグナル伝達経路

EGFR製品

  • All (110)
  • EGFR阻害剤 (104)
  • EGFR抗体(1)
  • EGFR活性剤(1)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S1025 Gefitinib Gefitinib is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.
Gastroenterology, 2024, S0016-5085(24)00062-3
Phytomedicine, 2024, 125:155351
mBio, 2024, e0228723.
S1023 Erlotinib HCl Erlotinib HCl is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Nat Commun, 2023, 14(1):1559
Nat Commun, 2023, 14(1):7863
Cell Rep, 2023, 42(8):112868
S7786 Erlotinib Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
NPJ Precis Oncol, 2024, 8(1):3
Transl Oncol, 2024, 39:101834
J Biol Chem, 2024, S0021-9258(24)00139-X
S2111 Lapatinib Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Drug Resist Updat, 2024, 73:101066
Nat Commun, 2023, 14(1):5035
Nat Commun, 2023, 10.1038/s41467-023-39059-3
S1011 Afatinib アファチニブ (Afatinib) は in vitro において EGFR/ErbB を不可逆的に阻害します。IC50 は EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4) に対してそれぞれ 0.5, 0.4, 10, 14 および 1 nM です。アファチニブによってオートファジー (autophagy) が誘発されることが報告されています。
Cell, 2024, 187(3):712-732.e38
Cell Rep, 2024, 43(1):113614
NPJ Precis Oncol, 2024, 8(1):3
S7297 Osimertinib (AZD9291) Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
NPJ Precis Oncol, 2024, 8(1):60
NPJ Precis Oncol, 2024, 8(1):3
Am J Cancer Res, 2024, 14(1):33-51
S1006 Saracatinib (AZD0530) Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.
Nat Commun, 2024, 15(1):1300
Nat Cancer, 2023, 4(2):240-256
Cancer Res, 2023, 83(1):141-157
S5098 Gefitinib hydrochloride Gefitinib (ZD1839) is an EGFR inhibitor with IC50s of 15.5 nM and 823.3 nM for WT EGFR and EGFR (858R/T790M), respectively.
Cancer Res, 2023, 83(2):316-331
Biochem Biophys Rep, 2023, 34:101436
Mol Cancer, 2022, 21(1):43
S7810 Afatinib Dimaleate Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
J Invest Dermatol, 2024, S0022-202X(23)03210-4
RSC Adv, 2023, 13(16):11037-11043
Biochem Biophys Rep, 2023, 34:101436
S1028 Lapatinib Ditosylate Lapatinib Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
Nat Commun, 2023, 14(1):3450
Int J Mol Sci, 2023, 24(7)6228
Cancers (Basel), 2023, 15(4)1216
S1143 AG-490 AG-490 is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Cytotherapy, 2024, 26(2):145-156
J Neuroinflammation, 2023, 20(1):87
iScience, 2023, 26(11):108211
S1046 Vandetanib Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Nat Cancer, 2023, 4(9):1345-1361
Cell Reports, 2023, 112328
Cell Rep, 2023, 42(4):112328
S1167 CP-724714 CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2.
Front Immunol, 2024, 15:1335302
Cell Signal, 2023, 106:110634
Cell Mol Immunol, 2022, 19(10):1153-1167.
S5078 Osimertinib mesylate Osimertinib mesylate (AZD9291) is the mesylate form of osimertinib, which is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug.
Nature, 2022, 603(7900):335-342
Mol Cancer, 2022, 21(1):43
Cancer Discov, 2022, CD-22-1074
S2150 Neratinib Neratinib is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays; weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3.
J Thorac Oncol, 2023, S1556-0864(23)00802-X
Cell Death Dis, 2023, 14(8):532
iScience, 2023, 26(3):106082
S2727 Dacomitinib Dacomitinib is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2.
Cell Rep Med, 2023, S2666-3791(23)00367-1
Cell Rep Med, 2023, 4(10):101200
J Thorac Oncol, 2023, S1556-0864(23)00802-X
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
mBio, 2024, e0228723.
JCI Insight, 2023, 8(1)e163929
Toxins (Basel), 2023, 16(1)21
S2192 Sapitinib (AZD8931) Sapitinib (AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2.
Cell Death Dis, 2023, 14(8):532
Adv Sci (Weinh), 2022, e2201539
BMC Cancer, 2022, 22(1):478
S1019 Canertinib (CI-1033) Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.
Cells, 2022, 11(3)425
Cells, 2022, 11(3)425
Front Mol Biosci, 2022, 9:952651
A2000 Cetuximab (anti-EGFR) Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.
J Exp Med, 2024, 221(2)e20230488
Cancer Res Commun, 2024, 4(1):118-133
Adv Sci (Weinh), 2023, 10(33):e2303619
S1173 WZ4002 WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I).
Cancer Metab, 2023, 11(1):20
Cancer Gene Ther, 2022, 29(12):1878-1894
Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w
S7284 Rociletinib (CO-1686) Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.
J Pers Med, 2022, 12(2)258
Hum Cell, 2022, 10.1007/s13577-022-00671-y
Cancer Cell, 2021, S1535-6108(21)00383-4
S2250 EGCG ((-)-Epigallocatechin Gallate) EGCG ((-)-Epigallocatechin Gallate) is the main catechin extraction of green tea that inhibits telomerase and DNA methyltransferase. EGCG blocks the activation of EGF receptors and HER-2 receptors. ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity.
Journal of Functional Foods, 2024, 105977
Cell Rep Med, 2023, 4(5):101026
Transl Oncol, 2023, 35:101712
S8229 Brigatinib Brigatinib is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits IGF-1R, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
NPJ Precis Oncol, 2023, 7(1):12
J Med Chem, 2023, 66(17):12130-12140
S1342 Genistein Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM.
Int J Nanomedicine, 2023, 18:4647-4662
Molecules, 2023, 28(4)1919
Exp Ther Med, 2023, 26(5):516
S7358 Poziotinib Poziotinib is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
J Thorac Oncol, 2023, S1556-0864(23)00802-X
JTO Clin Res Rep, 2023, 4(9):100554
S2205 DesMethyl Erlotinib (OSI-420) HCl DesMethyl Erlotinib (OSI-420) HCl is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
J Pharm Biomed Anal, 2023, 236:115716
Front Oncol, 2022, 12:939118
J Pers Med, 2022, 12(2)258
S1194 CUDC-101 CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.
Nat Commun, 2023, 14(1):2095
Nat Commun, 2023, 14(1):2095
J Transl Med, 2023, 21(1):604
S1079 PD153035 HCl PD153035 HCl (SU-5271 HCl, AG1517 HCl, ZM 252868 HCl) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.
J Biol Chem, 2022, 298(10):102419
Int J Mol Sci, 2021, 22(8)3945
FEBS Lett, 2021, 595(5):563-576
S2185 Allitinib tosylate Allitinib (AST-1306, AST-6) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.
Cells, 2022, 11(3)425
Cells, 2022, 11(3)425
Int J Mol Sci, 2022, 23(14)7774
S6546 PD153035 PD153035 is a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase (Ki = 5.2 pM).
Biomed Pharmacother, 2023, 158:114176
Cell Death Discov, 2023, 10.1038/s41420-023-01701-w
Sci Signal, 2022, 15(728):eabj6915
S8362 Tucatinib Tucatinib (Irbinitinib, ONT-380, ARRY-380) is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity.
J Thorac Oncol, 2023, S1556-0864(23)00802-X
Cell Death Dis, 2023, 14(8):532
Cancers (Basel), 2023, 15(4)1216
S1486 AEE788 (NVP-AEE788) AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.
Cell Rep Med, 2022, 3(1):100492
Genome Med, 2020, 18;12(1):17
Oncotarget, 2019, 10(68):7185-7197
S2867 WHI-P154 WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
Nat Commun, 2023, 14(1):6908
Nat Commun, 2023, 14(1):6908
Int J Mol Sci, 2023, 10.3390/ijms241813863
S1392 Pelitinib (EKB-569) Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Pelitinib (EKB-569) also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282 nM, 800 nM and 1255 nM, respectively. Phase2.
Cancer Cell, 2022, S1535-6108(22)00312-9
Cancer Discov, 2022, 12(5):1378-1395
Cell Oncol (Dordr), 2022, 45(4):601-619
S1056 AC480 (BMS-599626) AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1.
Int J Mol Sci, 2022, 23(22)14023
Genome Med, 2020, 18;12(1):17
Oncotarget, 2016, 7(24):36956-36970
S2755 Varlitinib Varlitinib (ARRY334543) is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2.
J Transl Med, 2023, 21(1):89
Cell Rep Med, 2022, 3(1):100492
Pharmaceutics, 2019, 11(11)
S0711 Canertinib dihydrochloride Canertinib (CI-1033, PD-183805, compound 18) dihydrochloride is a potent and irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Canertinib dihydrochloride inhibits cellular EGFR and ErbB2 autophosphorylation with IC50 of 7.4 nM and 9 nM, respectively.
Front Microbiol, 2022, 13:968872
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
Sci Rep, 2017,
S2922 Icotinib (BPI-2009H) Icotinib (BPI-2009H) is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).
Am J Cancer Res, 2024, 14(1):33-51
Cell Rep Med, 2022, 3(1):100492
Transl Res, 2022, S1931-5244(22)00244-4
S7824 Nazartinib (EGF816) Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro.
Cancer Cell, 2022, 40(7):754-767.e6
Sci Signal, 2022, 15(747):eabj5879
Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001
S7926 Lifirafenib (BGB-283) Lifirafenib (BGB-283, Beigene-283) potently inhibits RAF family kinases and EGFR activities in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
Sci Adv, 2023, 9(35):eade7486
Mol Cancer Ther, 2022, MCT-22-0004
Nat Commun, 2020, 11(1):3157
S8312 NSC228155 NSC228155 is an activator of EGFR. It binds to the sEGFR dimerization domain II and modulates EGFR tyrosine phosphorylation.
Adv Sci (Weinh), 2023, 10(24):e2207631
J Transl Med, 2023, 21(1):56
Biomed Res Int, 2023, 2023:4967544
S7000 AP26113-analog (ALK-IN-1) AP26113-analog (ALK-IN-1) is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.
Clin Cancer Res, 2015, 21(1):166-74
Clin Cancer Res, 2014, 20(22):5686-96
Clin Cancer Res, 2014, 20(22):5686-96
S7039 PD168393 PD168393 is an irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773; inactive against insulin, PDGFR, FGFR and PKC.
FEBS Open Bio, 2023, 10.1002/2211-5463.13653
J Neurosci Res, 2021, 10.1002/jnr.24909
Int J Biochem Cell Biol, 2019, 115:105578
S8294 Olmutinib (BI 1482694) Olmutinib (BI 1482694) is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.
Br J Pharmacol, 2022, 179(11):2754-2770
Ther Adv Med Oncol, 2022, 14:17588359221079125
Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001
S7971 Zorifertinib (AZD3759) Zorifertinib (AZD3759) is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.
Oncogene, 2022, 10.1038/s41388-022-02256-3
Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7
Clin Cancer Res, 2019, 25(8):2575-2587
S2784 TAK-285 TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
Oncotarget, 2020, 11(46):4224-4242
Mol Pharmacol, 2019, 95(5):528-536
Sci Signal, 2018, 11(549)
S2554 Daphnetin Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.
Sci Rep, 2021, 11(1):11491
Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7
Int Immunopharmacol, 2019, 72:195-203
S7298 AZ5104 AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.
J Pharm Biomed Anal, 2020, 177:112871
Clin Cancer Res, 2019, 25(8):2575-2587
Sci Rep, 2019, 9(1):5309
S8724 Lazertinib Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4.
J Exp Clin Cancer Res, 2023, 10.1186/s13046-023-02866-z
Cancer Res Treat, 2021, 10.4143/crt.2021.385
J Thorac Oncol, 2019, 14(9):1556-1566
S7557 CL-387785 (EKI-785) CL-387785 (EKI-785, WAY-EKI 785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM.
Nature, 2017, 550(7675):270-274
J Biol Chem, 2017, 292(24):10112-10122
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789
S8852 Pyrotinib dimaleate Pyrotinib dimaleate is a potent and selective irreversible dual tyrosine kinase inhibitor of EGFR and HER2 with IC50 of 0.013 μM and 0.038 μM, respectively.
Transl Lung Cancer Res, 2021, 10(8):3659-3670
Biomed Chromatogr, 2021, e5221
Clin Transl Med, 2020, 10(8):e254
S1179 WZ8040 WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).
Biochemistry, 2018, 57(8):1369-1379
Nat Commun, 2016, 7:10690
S7206 CNX-2006 CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w
Cancer Sci, 2016, 107(4):461-8
S6813 Mobocertinib (TAK788) Mobocertinib (TAK788, AP32788), an investigational TKI, is a potent, selective preclinical inhibitor of epidermal growth factor receptor (EGFR) and HER2 mutations. Mobocertinib (TAK788) is an antineoplastic agent.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
Lung Cancer, 2020, 152:135-142
S6868 Alflutinib (Furmonertinib) mesylate Alflutinib (Furmonertinib) mesylate is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations. Alflutinib (AST2818), primarily metabolized by CYP3A4, is also a potent CYP3A4 inducer with EC50 of 0.25 μM.
Int J Mol Sci, 2023, 24(18)13972
Int J Mol Sci, 2023, 24(18)13972
S0360 EGFR Inhibitor EGFR inhibitor, a cell permeable, 4,6-disubstituted pyrimidine compound, is a highly selevtive inhibitor of EGFR kinase with IC50 of 21 nM. EGFR inhibitor directly depolymerizes microtubules and is used as a chemical probe to investigate both the EGFR pathway and microtubule dynamics.
Cell Rep, 2022, 40-8:111223
Cancers (Basel), 2022, 14(19)4910
S2406 Chrysophanic Acid Chrysophanic Acid (Chrysophanol), a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor.
Cell Prolif, 2020, e12871
Naunyn Schmiedebergs Arch Pharmacol, 2019, 10.1007/s00210-019-01746-8
S3759 Norcantharidin Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Phytother Res, 2023, 10.1002/ptr.7963
Front Pharmacol, 2022, 13:1019478
S8036 Butein Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR.
Am J Cancer Res, 2020, 10(11):3721-3736
Oncotarget, 2015, 6(14):12637-53
S9414 Cyasterone Cyasterone is the main phytoecdysteroid component found in Cyathula capitata. It is a natural EGFR inhibitor and maybe a promising anti-cancer agent.
Chin Med, 2023, 18(1):136
Chin Med, 2023, 18(1):136
S8741 Avitinib (Abivertinib) Avitinib (Abivertinib) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type EGFR (IC50 value, 7.68 nM). It has comparable anti-tumor activity and tolerated toxicity.
Microsyst Nanoeng, 2023, 9:57
, 2022, 10.21203/rs.3.rs-2146794/v1
S1170 WZ3146 WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).
Aging (Albany NY), 2020, 12(19):19022-19044
S2752 HER2-Inhibitor-1 HER2-Inhibitor-1 is an analog of ARRY-380. ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.
Commun Biol, 2021, 4(1):762
S2895 Tyrphostin 9 Tyrphostin 9 (SF 6847, RG-50872) is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM.
Cell Rep, 2022, 38(10):110475
S8009 AG-18 AG-18 (RG-50810, Tyrphostin A23, TX 825) inhibits EGFR with IC50 of 35 μM.
Reproduction, 2016, 151(2):179-85
A2018 Panitumumab (anti-EGFR) Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).
Oncogene, 2023, 42(20):1620-1633
S6541 MTX-211 MTX-211 is a first-in-class dual inhibitor of PI3K and EGFR kinase.
Int J Mol Sci, 2023, 24(8)7608
S8412 Naquotinib(ASP8273) Naquotinib (ASP8273) is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity.
Expert Opin Emerg Drugs, 2018, 10.1080/14728214.2018.1558203 Share on FacebookShare on TwitterShare on Google+
S9786 Tuxobertinib (BDTX-189) Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. BDTX-189 exhibits anticancer activity.
J Transl Med, 2023, 21(1):89
S4667 Lidocaine hydrochloride Lidocaine hydrochloride (Lidothesin, Lignocaine, Xyloneural) is an inhibitor of epidermal growth factor receptor (EGFR) and has antiproliferative effect on human tongue cancer cells. Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent.
Exp Ther Med, 2021, 21(5):424
E0368 Sunvozertinib (DZD9008) Sunvozertinib (DZD9008) is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

J Thorac Oncol, 2023, S1556-0864(23)00797-9
S8242 EAI045 EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
EJNMMI Res, 2024, 14(1):19
Pharmazie, 2018, 73(11):630-634
S8814 zipalertinib TAS6417 (CLN-081, TPC-064) is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
S8817 Almonertinib (HS-10296) Almonertinib (HS-10296) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
Biochem Pharmacol, 2021, 188:114516
E4449New AG 825 AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells.
E1749New limertinib limertinib (ASK120067) is an irreversible third-generation inhibitor of EGFRT790M with IC50 of 0.3 nM, with selectivity over EGFRWT having IC50 of 6.0 nM. It exhibits potent anti-proliferation activity in non-small cell lung cancer (NSCLC) tumor cells.
S6899 Licochalcone D Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S6525 AG 555 AG-555 (Tyrphostin B46) is an inhibitor of tyrosine kinase, interacts directly with topoisomerase I, thus preventing DNA relaxation. It inhibits EGFR with an IC50 of 0.7 μM.
E1176 BLU-945

BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 facilitates efficacious dosing and reduces EGFR-mediated on-target toxicities. S BLU-945 has the potential for the research of cancer disease (extracted from patent WO2021133809A1, compound 112).

S6805 Tyrphostin AG-528 Tyrphostin AG-528 (Tyrphostin B66) is a potent inhibitor of epidermal growth factor receptors (EGFR) and ErbB2/HER2 with IC50 of 4.9 μM and 2.1 μM, respectively. Tyrphostin AG-528 exhibits anticancer activity.
S6509 AG 494 AG-494, a member of the tyrphostin family of tyrosine kinase inhibitors, is a potent inhibitor of EGF receptor autophosphorylation (IC50=1.2 μM) and EGF-dependent cell growth (IC50=6 μM).
S0736 AG 556 AG-556 is a potent EGFR tyrphostin inhibitor with an IC50 of 5µM which suppresses the EGF-induced growth of HER14 cell.
S6523 RG14620 RG14620 (Tyrphostin RG14620), an EGFR inhibitor of the tyrphostin family, directly inhibits the transport function of ABCG2/BCRP.
S6530 EBE-A22 EBE-A22 is a derivative of PD 153035 which can inhibit ErbB-1-phosphorylation, whereas EBE-A22 is inactive.
S0070 Gefitinib-based PROTAC 3 Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively.
S0324 Tyrphostin AG30 (AG30) Tyrphostin AG30 (AG30), a potent and selective EGFR tyrosine kinase inhibitor, selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts.
E0344 ErbB2 inhibitor ErbB-2 Inhibitor is a EGFR, ErbB2 and ErbB4 inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM.
S6698 TQB3804 TQB3804 is a selective and potent EGFR kinase inhibitor with IC50 of 0.46 nM, 0.13 nM, 0.26 nM, 0.19 nM and 1.07 nM for for EGFRd746-750/T790M/C797S, EGFRL858R/T790M/C797S, EGFRd746-750/T790M, EGFRL858R/T790M and EGFRWT, respectively. TQB3804 (EGFR-IN-7) shows anti-tumor activity.
S3879 Kaempferide Kaempferide (4'-Methylkaempferol, 4'-O-Methylkaempferol, Kaempferol 4'-methyl ether), a natural compound derived from the roots of kaempferia galanga, has a variety of effects including anti-carcinogenic, anti-inflammatory, anti-oxidant, anti-bacterial and anti-viral properties.
S2733 AV-412 free base AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.51, 0.79, 2.30, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.
E0822 AST-1306 AST-1306 (Allitinib) is an orally active and irreversible EGFR, ErbB2 and inhibitor with IC50s of 0.5, 3 and 0.8 nM, respectively.
S8920 (Rac)-JBJ-04-125-02 (Rac)-JBJ-04-125-02 (JBJ-04-125-02 racemate) is a mutant-selective allosteric inhibitor of Epidermal growth factor receptor (EGFR) with potential anticancer activity.
S6881 JND3229 JND3229 is a potent reversible inhibitor of EGFRC797S with an IC50 value of 5.8 nM. JND3229 also potently suppresses EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 nM and 6.8 nM, respectively.
S8921 BI-4020 BI-4020 is an orally active, non-covalent EGFR inhibitor with IC50 of 0.6 nM and 0.2 nM for EGFRdel19 T790M C797S as biomarker potency and anti-proliferation potency in BaF3 cells, respectively.
S1054 AG99 AG99 (Tyrphostin 46,Tyrphostin A46,Tyrphostin B40) is a potent and selective inhibitor of EGFR.
S8584 Theliatinib (HMPL-309) Theliatinib (HMPL-309) is a highly potent EGFR inhibitor with Ki value of 0.05 nM against the wild type EGFR and IC50 values of 3 nM and 22 nM against EGFR and EGFR T790M/L858R mutant. It demonstrats 50 fold greater selectivity for EGFR compared to 72 other kinases.
S0151 AG-1557 AG-1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
S2115 RG 13022 RG 13022 (Tyrphostin RG13022) inhibits the autophosphorylation reaction of the EGF receptor in immunoprecipitates with IC50 of 4 µM.
E1478New BDTX-1535 BDTX-1535 (EGFR-IN-76) is an orally available, highly potent, selective, and irreversible EGFR inhibitor that can penetrate the blood-brain barrier, with the potential to treat Glioblastoma or Non-Small Cell Lung Cancer.
E2399 Falnidamol Falnidamol (BIBX1382) is a selective inhibitor of epidermal growth factor receptor (EGFR), exerting anti-cancer role in human head and neck squamous cell carcinomas both in vitro and in vivo through suppressing mitogen-activated protein kinases (MAPKs) signaling.
E0833 O-Demethyl-Gefitinib O-Desmethyl gefitinib, a major active metabolite of gefitinib, is a potent EGFR (ErbB1/HER1) inhibitor, inhibits subcellular EGFR tyrosine kinase through a mechanism similar to that of gefitinib with IC50 values of 36 and 22 nM, respectively.
D4022New Cetuximab-MMAE Cetuximab-MMAE is an antibody-drug conjugate composed of a anti-EGFR monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker.
D4027New Serclutamab talirine Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands.
D4037New Laprituximab emtansine Laprituximab emtansine (IMGN-289) is an anti-EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB), chimeric monoclonal antibody conjugated to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, forming a nonreducible thioether bond.
S6897 Epertinib hydrochloride Epertinib hydrochloride (S-222611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4 with IC50 of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride (S-222611 hydrochloride) exhibits antitumor activity.
S6809 SU5214 SU5214 is an inhibitor of VEGF receptor 2 (VEGFR2/FLK-1) with IC50 of 14.8 µM and EGFR with IC50 of 36.7 µm, respectively.
D4042New Depatuxizumab mafodotin Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM).
D4049New Disitamab vedotin Disitamab Vedotin (RC-48 ,RC 480-ADC) is an antibody-drug conjugate(ADC) composed of anti-[ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] humanized monoclonal antibody, conjugated to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Disitamab Vedotin has the potential for use in solid tumors mainly in advanced breast cancer.
E2980New 4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 4-AMino-1-phenylpyrazole[3,4-d]pyriMidine(PP 3) is an EGFR tyrosine kinase inhibitor with an IC50 of 2.7 μM. It is a negative control for the Src kinase inhibitor, PP 2.
A2018 Panitumumab (anti-EGFR) Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).
Oncogene, 2023, 42(20):1620-1633
S1025 Gefitinib Gefitinib is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.
Gastroenterology, 2024, S0016-5085(24)00062-3
Phytomedicine, 2024, 125:155351
mBio, 2024, e0228723.
S1023 Erlotinib HCl Erlotinib HCl is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Nat Commun, 2023, 14(1):1559
Nat Commun, 2023, 14(1):7863
Cell Rep, 2023, 42(8):112868
S7786 Erlotinib Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
NPJ Precis Oncol, 2024, 8(1):3
Transl Oncol, 2024, 39:101834
J Biol Chem, 2024, S0021-9258(24)00139-X
S2111 Lapatinib Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Drug Resist Updat, 2024, 73:101066
Nat Commun, 2023, 14(1):5035
Nat Commun, 2023, 10.1038/s41467-023-39059-3
S1011 Afatinib アファチニブ (Afatinib) は in vitro において EGFR/ErbB を不可逆的に阻害します。IC50 は EGFRwt, EGFR L858R , EGFR L858R/T790M ErbB2 (HER2) and ErbB4 (HER4) に対してそれぞれ 0.5, 0.4, 10, 14 および 1 nM です。アファチニブによってオートファジー (autophagy) が誘発されることが報告されています。
Cell, 2024, 187(3):712-732.e38
Cell Rep, 2024, 43(1):113614
NPJ Precis Oncol, 2024, 8(1):3
S7297 Osimertinib (AZD9291) Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
NPJ Precis Oncol, 2024, 8(1):60
NPJ Precis Oncol, 2024, 8(1):3
Am J Cancer Res, 2024, 14(1):33-51
S1006 Saracatinib (AZD0530) Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.
Nat Commun, 2024, 15(1):1300
Nat Cancer, 2023, 4(2):240-256
Cancer Res, 2023, 83(1):141-157
S5098 Gefitinib hydrochloride Gefitinib (ZD1839) is an EGFR inhibitor with IC50s of 15.5 nM and 823.3 nM for WT EGFR and EGFR (858R/T790M), respectively.
Cancer Res, 2023, 83(2):316-331
Biochem Biophys Rep, 2023, 34:101436
Mol Cancer, 2022, 21(1):43
S7810 Afatinib Dimaleate Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
J Invest Dermatol, 2024, S0022-202X(23)03210-4
RSC Adv, 2023, 13(16):11037-11043
Biochem Biophys Rep, 2023, 34:101436
S1028 Lapatinib Ditosylate Lapatinib Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
Nat Commun, 2023, 14(1):3450
Int J Mol Sci, 2023, 24(7)6228
Cancers (Basel), 2023, 15(4)1216
S1143 AG-490 AG-490 is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Cytotherapy, 2024, 26(2):145-156
J Neuroinflammation, 2023, 20(1):87
iScience, 2023, 26(11):108211
S1046 Vandetanib Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay. It also inhibits VEGFR3 and EGFR with IC50 of 110 nM and 500 nM, respectively. Not sensitive to PDGFRβ, Flt1, Tie-2 and FGFR1 with IC50 of 1.1-3.6 μM. No activity against MEK, CDK2, c-Kit, erbB2, FAK, PDK1, Akt and IGF-1R with IC50 above 10 μM. Vandetanib (ZD6474) increases apoptosis and induces autophagy by increasing the level of reactive oxygen species (ROS).
Nat Cancer, 2023, 4(9):1345-1361
Cell Reports, 2023, 112328
Cell Rep, 2023, 42(4):112328
S1167 CP-724714 CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2.
Front Immunol, 2024, 15:1335302
Cell Signal, 2023, 106:110634
Cell Mol Immunol, 2022, 19(10):1153-1167.
S5078 Osimertinib mesylate Osimertinib mesylate (AZD9291) is the mesylate form of osimertinib, which is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug.
Nature, 2022, 603(7900):335-342
Mol Cancer, 2022, 21(1):43
Cancer Discov, 2022, CD-22-1074
S2150 Neratinib Neratinib is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays; weakly inhibits KDR and Src, no significant inhibition to Akt, CDK1/2/4, IKK-2, MK-2, PDK1, c-Raf and c-Met. Phase 3.
J Thorac Oncol, 2023, S1556-0864(23)00802-X
Cell Death Dis, 2023, 14(8):532
iScience, 2023, 26(3):106082
S2727 Dacomitinib Dacomitinib is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay. Dacomitinib inhibits ERBB2 and ERBB4 with IC50 of 45.7 nM and 73.7 nM, respectively. Dacomitinib is effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Dacomitinib inhibits cell growth and induces apoptosis. Phase 2.
Cell Rep Med, 2023, S2666-3791(23)00367-1
Cell Rep Med, 2023, 4(10):101200
J Thorac Oncol, 2023, S1556-0864(23)00802-X
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
mBio, 2024, e0228723.
JCI Insight, 2023, 8(1)e163929
Toxins (Basel), 2023, 16(1)21
S2192 Sapitinib (AZD8931) Sapitinib (AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2.
Cell Death Dis, 2023, 14(8):532
Adv Sci (Weinh), 2022, e2201539
BMC Cancer, 2022, 22(1):478
S1019 Canertinib (CI-1033) Canertinib (CI-1033, PD183805) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. Phase 3.
Cells, 2022, 11(3)425
Cells, 2022, 11(3)425
Front Mol Biosci, 2022, 9:952651
S1173 WZ4002 WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I).
Cancer Metab, 2023, 11(1):20
Cancer Gene Ther, 2022, 29(12):1878-1894
Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w
S7284 Rociletinib (CO-1686) Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.
J Pers Med, 2022, 12(2)258
Hum Cell, 2022, 10.1007/s13577-022-00671-y
Cancer Cell, 2021, S1535-6108(21)00383-4
S2250 EGCG ((-)-Epigallocatechin Gallate) EGCG ((-)-Epigallocatechin Gallate) is the main catechin extraction of green tea that inhibits telomerase and DNA methyltransferase. EGCG blocks the activation of EGF receptors and HER-2 receptors. ECGG inhibits fatty acid synthase and glutamate dehydrogenase activity.
Journal of Functional Foods, 2024, 105977
Cell Rep Med, 2023, 4(5):101026
Transl Oncol, 2023, 35:101712
S8229 Brigatinib Brigatinib is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits IGF-1R, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
NPJ Precis Oncol, 2023, 7(1):12
J Med Chem, 2023, 66(17):12130-12140
S1342 Genistein Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM.
Int J Nanomedicine, 2023, 18:4647-4662
Molecules, 2023, 28(4)1919
Exp Ther Med, 2023, 26(5):516
S7358 Poziotinib Poziotinib is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
J Thorac Oncol, 2023, S1556-0864(23)00802-X
JTO Clin Res Rep, 2023, 4(9):100554
S2205 DesMethyl Erlotinib (OSI-420) HCl DesMethyl Erlotinib (OSI-420) HCl is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).
J Pharm Biomed Anal, 2023, 236:115716
Front Oncol, 2022, 12:939118
J Pers Med, 2022, 12(2)258
S1194 CUDC-101 CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.
Nat Commun, 2023, 14(1):2095
Nat Commun, 2023, 14(1):2095
J Transl Med, 2023, 21(1):604
S1079 PD153035 HCl PD153035 HCl (SU-5271 HCl, AG1517 HCl, ZM 252868 HCl) is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.
J Biol Chem, 2022, 298(10):102419
Int J Mol Sci, 2021, 22(8)3945
FEBS Lett, 2021, 595(5):563-576
S2185 Allitinib tosylate Allitinib (AST-1306, AST-6) is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.
Cells, 2022, 11(3)425
Cells, 2022, 11(3)425
Int J Mol Sci, 2022, 23(14)7774
S6546 PD153035 PD153035 is a specific and potent inhibitor of the epidermal growth factor (EGF) receptor tyrosine kinase (Ki = 5.2 pM).
Biomed Pharmacother, 2023, 158:114176
Cell Death Discov, 2023, 10.1038/s41420-023-01701-w
Sci Signal, 2022, 15(728):eabj6915
S8362 Tucatinib Tucatinib (Irbinitinib, ONT-380, ARRY-380) is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity.
J Thorac Oncol, 2023, S1556-0864(23)00802-X
Cell Death Dis, 2023, 14(8):532
Cancers (Basel), 2023, 15(4)1216
S1486 AEE788 (NVP-AEE788) AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.
Cell Rep Med, 2022, 3(1):100492
Genome Med, 2020, 18;12(1):17
Oncotarget, 2019, 10(68):7185-7197
S2867 WHI-P154 WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.
Nat Commun, 2023, 14(1):6908
Nat Commun, 2023, 14(1):6908
Int J Mol Sci, 2023, 10.3390/ijms241813863
S1392 Pelitinib (EKB-569) Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Pelitinib (EKB-569) also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282 nM, 800 nM and 1255 nM, respectively. Phase2.
Cancer Cell, 2022, S1535-6108(22)00312-9
Cancer Discov, 2022, 12(5):1378-1395
Cell Oncol (Dordr), 2022, 45(4):601-619
S1056 AC480 (BMS-599626) AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1.
Int J Mol Sci, 2022, 23(22)14023
Genome Med, 2020, 18;12(1):17
Oncotarget, 2016, 7(24):36956-36970
S2755 Varlitinib Varlitinib (ARRY334543) is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2.
J Transl Med, 2023, 21(1):89
Cell Rep Med, 2022, 3(1):100492
Pharmaceutics, 2019, 11(11)
S0711 Canertinib dihydrochloride Canertinib (CI-1033, PD-183805, compound 18) dihydrochloride is a potent and irreversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Canertinib dihydrochloride inhibits cellular EGFR and ErbB2 autophosphorylation with IC50 of 7.4 nM and 9 nM, respectively.
Front Microbiol, 2022, 13:968872
Acta Physiol (Oxf), 2021, 10.1111/apha.13661
Sci Rep, 2017,
S2922 Icotinib (BPI-2009H) Icotinib (BPI-2009H) is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).
Am J Cancer Res, 2024, 14(1):33-51
Cell Rep Med, 2022, 3(1):100492
Transl Res, 2022, S1931-5244(22)00244-4
S7824 Nazartinib (EGF816) Nazartinib (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (L858R, ex19del) and T790M mt, with up to 60-fold selectivity over wild type (wt) EGFR in vitro.
Cancer Cell, 2022, 40(7):754-767.e6
Sci Signal, 2022, 15(747):eabj5879
Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001
S7926 Lifirafenib (BGB-283) Lifirafenib (BGB-283, Beigene-283) potently inhibits RAF family kinases and EGFR activities in biochemical assays with IC50 values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant.
Sci Adv, 2023, 9(35):eade7486
Mol Cancer Ther, 2022, MCT-22-0004
Nat Commun, 2020, 11(1):3157
S7000 AP26113-analog (ALK-IN-1) AP26113-analog (ALK-IN-1) is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR.
Clin Cancer Res, 2015, 21(1):166-74
Clin Cancer Res, 2014, 20(22):5686-96
Clin Cancer Res, 2014, 20(22):5686-96
S7039 PD168393 PD168393 is an irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773; inactive against insulin, PDGFR, FGFR and PKC.
FEBS Open Bio, 2023, 10.1002/2211-5463.13653
J Neurosci Res, 2021, 10.1002/jnr.24909
Int J Biochem Cell Biol, 2019, 115:105578
S8294 Olmutinib (BI 1482694) Olmutinib (BI 1482694) is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.
Br J Pharmacol, 2022, 179(11):2754-2770
Ther Adv Med Oncol, 2022, 14:17588359221079125
Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001
S7971 Zorifertinib (AZD3759) Zorifertinib (AZD3759) is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.
Oncogene, 2022, 10.1038/s41388-022-02256-3
Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7
Clin Cancer Res, 2019, 25(8):2575-2587
S2784 TAK-285 TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.
Oncotarget, 2020, 11(46):4224-4242
Mol Pharmacol, 2019, 95(5):528-536
Sci Signal, 2018, 11(549)
S2554 Daphnetin Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.
Sci Rep, 2021, 11(1):11491
Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7
Int Immunopharmacol, 2019, 72:195-203
S7298 AZ5104 AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.
J Pharm Biomed Anal, 2020, 177:112871
Clin Cancer Res, 2019, 25(8):2575-2587
Sci Rep, 2019, 9(1):5309
S8724 Lazertinib Lazertinib (YH25448,GNS-1480) is a potent, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively, showing much higher IC50 values aganist ErbB2 and ErbB4.
J Exp Clin Cancer Res, 2023, 10.1186/s13046-023-02866-z
Cancer Res Treat, 2021, 10.4143/crt.2021.385
J Thorac Oncol, 2019, 14(9):1556-1566
S7557 CL-387785 (EKI-785) CL-387785 (EKI-785, WAY-EKI 785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM.
Nature, 2017, 550(7675):270-274
J Biol Chem, 2017, 292(24):10112-10122
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789
S8852 Pyrotinib dimaleate Pyrotinib dimaleate is a potent and selective irreversible dual tyrosine kinase inhibitor of EGFR and HER2 with IC50 of 0.013 μM and 0.038 μM, respectively.
Transl Lung Cancer Res, 2021, 10(8):3659-3670
Biomed Chromatogr, 2021, e5221
Clin Transl Med, 2020, 10(8):e254
S1179 WZ8040 WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).
Biochemistry, 2018, 57(8):1369-1379
Nat Commun, 2016, 7:10690
S7206 CNX-2006 CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
Nat Nanotechnol, 2021, 10.1038/s41565-021-00872-w
Cancer Sci, 2016, 107(4):461-8
S6813 Mobocertinib (TAK788) Mobocertinib (TAK788, AP32788), an investigational TKI, is a potent, selective preclinical inhibitor of epidermal growth factor receptor (EGFR) and HER2 mutations. Mobocertinib (TAK788) is an antineoplastic agent.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
Lung Cancer, 2020, 152:135-142
S6868 Alflutinib (Furmonertinib) mesylate Alflutinib (Furmonertinib) mesylate is a third-generation epidermal growth factor receptor (EGFR) inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations. Alflutinib (AST2818), primarily metabolized by CYP3A4, is also a potent CYP3A4 inducer with EC50 of 0.25 μM.
Int J Mol Sci, 2023, 24(18)13972
Int J Mol Sci, 2023, 24(18)13972
S0360 EGFR Inhibitor EGFR inhibitor, a cell permeable, 4,6-disubstituted pyrimidine compound, is a highly selevtive inhibitor of EGFR kinase with IC50 of 21 nM. EGFR inhibitor directly depolymerizes microtubules and is used as a chemical probe to investigate both the EGFR pathway and microtubule dynamics.
Cell Rep, 2022, 40-8:111223
Cancers (Basel), 2022, 14(19)4910
S2406 Chrysophanic Acid Chrysophanic Acid (Chrysophanol), a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor.
Cell Prolif, 2020, e12871
Naunyn Schmiedebergs Arch Pharmacol, 2019, 10.1007/s00210-019-01746-8
S3759 Norcantharidin Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
Phytother Res, 2023, 10.1002/ptr.7963
Front Pharmacol, 2022, 13:1019478
S8036 Butein Butein, a plant polyphenol isolated from Rhus verniciflua, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR.
Am J Cancer Res, 2020, 10(11):3721-3736
Oncotarget, 2015, 6(14):12637-53
S9414 Cyasterone Cyasterone is the main phytoecdysteroid component found in Cyathula capitata. It is a natural EGFR inhibitor and maybe a promising anti-cancer agent.
Chin Med, 2023, 18(1):136
Chin Med, 2023, 18(1):136
S8741 Avitinib (Abivertinib) Avitinib (Abivertinib) is a pyrrolopyrimidine-based irreversible EGFR inhibitor that is mutation-selective with IC50 value of 0.18 nM against EGFR L858R/T790M double mutations, nearly 43-fold greater potency over wild-type EGFR (IC50 value, 7.68 nM). It has comparable anti-tumor activity and tolerated toxicity.
Microsyst Nanoeng, 2023, 9:57
, 2022, 10.21203/rs.3.rs-2146794/v1
S1170 WZ3146 WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).
Aging (Albany NY), 2020, 12(19):19022-19044
S2752 HER2-Inhibitor-1 HER2-Inhibitor-1 is an analog of ARRY-380. ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.
Commun Biol, 2021, 4(1):762
S2895 Tyrphostin 9 Tyrphostin 9 (SF 6847, RG-50872) is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM.
Cell Rep, 2022, 38(10):110475
S8009 AG-18 AG-18 (RG-50810, Tyrphostin A23, TX 825) inhibits EGFR with IC50 of 35 μM.
Reproduction, 2016, 151(2):179-85
S6541 MTX-211 MTX-211 is a first-in-class dual inhibitor of PI3K and EGFR kinase.
Int J Mol Sci, 2023, 24(8)7608
S8412 Naquotinib(ASP8273) Naquotinib (ASP8273) is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity.
Expert Opin Emerg Drugs, 2018, 10.1080/14728214.2018.1558203 Share on FacebookShare on TwitterShare on Google+
S9786 Tuxobertinib (BDTX-189) Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations with Kd of 0.2 nM, 0.76 nM, 13 nM and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. BDTX-189 exhibits anticancer activity.
J Transl Med, 2023, 21(1):89
S4667 Lidocaine hydrochloride Lidocaine hydrochloride (Lidothesin, Lignocaine, Xyloneural) is an inhibitor of epidermal growth factor receptor (EGFR) and has antiproliferative effect on human tongue cancer cells. Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmia agent.
Exp Ther Med, 2021, 21(5):424
E0368 Sunvozertinib (DZD9008) Sunvozertinib (DZD9008) is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

J Thorac Oncol, 2023, S1556-0864(23)00797-9
S8242 EAI045 EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.
EJNMMI Res, 2024, 14(1):19
Pharmazie, 2018, 73(11):630-634
S8814 zipalertinib TAS6417 (CLN-081, TPC-064) is a novel EGFR inhibitor that targets EGFR exon 20 insertion mutations while sparing wild-type (WT) EGFR. IC50 values ranges from 1.1 ± 0.1 to 8.0 ± 1.1 nmol/L.
J Thorac Oncol, 2023, S1556-0864(23)00797-9
S8817 Almonertinib (HS-10296) Almonertinib (HS-10296) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
Biochem Pharmacol, 2021, 188:114516
E4449New AG 825 AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells.
E1749New limertinib limertinib (ASK120067) is an irreversible third-generation inhibitor of EGFRT790M with IC50 of 0.3 nM, with selectivity over EGFRWT having IC50 of 6.0 nM. It exhibits potent anti-proliferation activity in non-small cell lung cancer (NSCLC) tumor cells.
S6899 Licochalcone D Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S6525 AG 555 AG-555 (Tyrphostin B46) is an inhibitor of tyrosine kinase, interacts directly with topoisomerase I, thus preventing DNA relaxation. It inhibits EGFR with an IC50 of 0.7 μM.
E1176 BLU-945

BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 facilitates efficacious dosing and reduces EGFR-mediated on-target toxicities. S BLU-945 has the potential for the research of cancer disease (extracted from patent WO2021133809A1, compound 112).

S6805 Tyrphostin AG-528 Tyrphostin AG-528 (Tyrphostin B66) is a potent inhibitor of epidermal growth factor receptors (EGFR) and ErbB2/HER2 with IC50 of 4.9 μM and 2.1 μM, respectively. Tyrphostin AG-528 exhibits anticancer activity.
S6509 AG 494 AG-494, a member of the tyrphostin family of tyrosine kinase inhibitors, is a potent inhibitor of EGF receptor autophosphorylation (IC50=1.2 μM) and EGF-dependent cell growth (IC50=6 μM).
S0736 AG 556 AG-556 is a potent EGFR tyrphostin inhibitor with an IC50 of 5µM which suppresses the EGF-induced growth of HER14 cell.
S6523 RG14620 RG14620 (Tyrphostin RG14620), an EGFR inhibitor of the tyrphostin family, directly inhibits the transport function of ABCG2/BCRP.
S0070 Gefitinib-based PROTAC 3 Gefitinib-based PROTAC 3 which conjugates an EGFR binding element to a VHL ligand via a linker induces degradation of EGFR and mutants with DC50 of 11.7 nM and 22.3 nM in HCC827(Exon 19 del) and H3255 (L858R) cells, respectively.
S0324 Tyrphostin AG30 (AG30) Tyrphostin AG30 (AG30), a potent and selective EGFR tyrosine kinase inhibitor, selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts.
E0344 ErbB2 inhibitor ErbB-2 Inhibitor is a EGFR, ErbB2 and ErbB4 inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM.
S6698 TQB3804 TQB3804 is a selective and potent EGFR kinase inhibitor with IC50 of 0.46 nM, 0.13 nM, 0.26 nM, 0.19 nM and 1.07 nM for for EGFRd746-750/T790M/C797S, EGFRL858R/T790M/C797S, EGFRd746-750/T790M, EGFRL858R/T790M and EGFRWT, respectively. TQB3804 (EGFR-IN-7) shows anti-tumor activity.
S2733 AV-412 free base AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.51, 0.79, 2.30, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.
E0822 AST-1306 AST-1306 (Allitinib) is an orally active and irreversible EGFR, ErbB2 and inhibitor with IC50s of 0.5, 3 and 0.8 nM, respectively.
S8920 (Rac)-JBJ-04-125-02 (Rac)-JBJ-04-125-02 (JBJ-04-125-02 racemate) is a mutant-selective allosteric inhibitor of Epidermal growth factor receptor (EGFR) with potential anticancer activity.
S6881 JND3229 JND3229 is a potent reversible inhibitor of EGFRC797S with an IC50 value of 5.8 nM. JND3229 also potently suppresses EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 nM and 6.8 nM, respectively.
S8921 BI-4020 BI-4020 is an orally active, non-covalent EGFR inhibitor with IC50 of 0.6 nM and 0.2 nM for EGFRdel19 T790M C797S as biomarker potency and anti-proliferation potency in BaF3 cells, respectively.
S1054 AG99 AG99 (Tyrphostin 46,Tyrphostin A46,Tyrphostin B40) is a potent and selective inhibitor of EGFR.
S8584 Theliatinib (HMPL-309) Theliatinib (HMPL-309) is a highly potent EGFR inhibitor with Ki value of 0.05 nM against the wild type EGFR and IC50 values of 3 nM and 22 nM against EGFR and EGFR T790M/L858R mutant. It demonstrats 50 fold greater selectivity for EGFR compared to 72 other kinases.
S0151 AG-1557 AG-1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
S2115 RG 13022 RG 13022 (Tyrphostin RG13022) inhibits the autophosphorylation reaction of the EGF receptor in immunoprecipitates with IC50 of 4 µM.
E1478New BDTX-1535 BDTX-1535 (EGFR-IN-76) is an orally available, highly potent, selective, and irreversible EGFR inhibitor that can penetrate the blood-brain barrier, with the potential to treat Glioblastoma or Non-Small Cell Lung Cancer.
E2399 Falnidamol Falnidamol (BIBX1382) is a selective inhibitor of epidermal growth factor receptor (EGFR), exerting anti-cancer role in human head and neck squamous cell carcinomas both in vitro and in vivo through suppressing mitogen-activated protein kinases (MAPKs) signaling.
E0833 O-Demethyl-Gefitinib O-Desmethyl gefitinib, a major active metabolite of gefitinib, is a potent EGFR (ErbB1/HER1) inhibitor, inhibits subcellular EGFR tyrosine kinase through a mechanism similar to that of gefitinib with IC50 values of 36 and 22 nM, respectively.
D4022New Cetuximab-MMAE Cetuximab-MMAE is an antibody-drug conjugate composed of a anti-EGFR monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker.
D4027New Serclutamab talirine Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands.
D4037New Laprituximab emtansine Laprituximab emtansine (IMGN-289) is an anti-EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB), chimeric monoclonal antibody conjugated to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, forming a nonreducible thioether bond.
S6897 Epertinib hydrochloride Epertinib hydrochloride (S-222611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4 with IC50 of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride (S-222611 hydrochloride) exhibits antitumor activity.
S6809 SU5214 SU5214 is an inhibitor of VEGF receptor 2 (VEGFR2/FLK-1) with IC50 of 14.8 µM and EGFR with IC50 of 36.7 µm, respectively.
E2980New 4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 4-AMino-1-phenylpyrazole[3,4-d]pyriMidine(PP 3) is an EGFR tyrosine kinase inhibitor with an IC50 of 2.7 μM. It is a negative control for the Src kinase inhibitor, PP 2.
A2000 Cetuximab (anti-EGFR) Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.
J Exp Med, 2024, 221(2)e20230488
Cancer Res Commun, 2024, 4(1):118-133
Adv Sci (Weinh), 2023, 10(33):e2303619
S8312 NSC228155 NSC228155 is an activator of EGFR. It binds to the sEGFR dimerization domain II and modulates EGFR tyrosine phosphorylation.
Adv Sci (Weinh), 2023, 10(24):e2207631
J Transl Med, 2023, 21(1):56
Biomed Res Int, 2023, 2023:4967544
E4449New AG 825 AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells.
E1749New limertinib limertinib (ASK120067) is an irreversible third-generation inhibitor of EGFRT790M with IC50 of 0.3 nM, with selectivity over EGFRWT having IC50 of 6.0 nM. It exhibits potent anti-proliferation activity in non-small cell lung cancer (NSCLC) tumor cells.
E1478New BDTX-1535 BDTX-1535 (EGFR-IN-76) is an orally available, highly potent, selective, and irreversible EGFR inhibitor that can penetrate the blood-brain barrier, with the potential to treat Glioblastoma or Non-Small Cell Lung Cancer.
D4022New Cetuximab-MMAE Cetuximab-MMAE is an antibody-drug conjugate composed of a anti-EGFR monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker.
D4027New Serclutamab talirine Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands.
D4037New Laprituximab emtansine Laprituximab emtansine (IMGN-289) is an anti-EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB), chimeric monoclonal antibody conjugated to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, forming a nonreducible thioether bond.
D4042New Depatuxizumab mafodotin Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM).
D4049New Disitamab vedotin Disitamab Vedotin (RC-48 ,RC 480-ADC) is an antibody-drug conjugate(ADC) composed of anti-[ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] humanized monoclonal antibody, conjugated to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Disitamab Vedotin has the potential for use in solid tumors mainly in advanced breast cancer.
E2980New 4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 4-AMino-1-phenylpyrazole[3,4-d]pyriMidine(PP 3) is an EGFR tyrosine kinase inhibitor with an IC50 of 2.7 μM. It is a negative control for the Src kinase inhibitor, PP 2.

EGFR阻害剤の選択性比較

Tags: EGFR inhibition | EGFR cancer | EGFR tumor | EGFR activation | EGFR signaling pathway | EGFR phosphorylation | EGFR targets | EGFR inhibitor drugs | EGFR inhibitors cancer | EGFR assay | EGFR activity | EGFR inhibitors list | EGFR inhibitor review